NO20044462L - Anvendelse av EP4-reseptorligander i behandling av IL-6 involverte sykdommer - Google Patents

Anvendelse av EP4-reseptorligander i behandling av IL-6 involverte sykdommer

Info

Publication number
NO20044462L
NO20044462L NO20044462A NO20044462A NO20044462L NO 20044462 L NO20044462 L NO 20044462L NO 20044462 A NO20044462 A NO 20044462A NO 20044462 A NO20044462 A NO 20044462A NO 20044462 L NO20044462 L NO 20044462L
Authority
NO
Norway
Prior art keywords
treatment
receptor ligands
involved diseases
whole blood
relates
Prior art date
Application number
NO20044462A
Other languages
English (en)
Inventor
Kana Taniguchi
Masato Shimojo
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of NO20044462L publication Critical patent/NO20044462L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Foreliggende oppfinnelse angår anvendelse av en EP4-reseptor-ligand ved fremstilling av et medikament for behandling av IL-6 involverte sykdommer. Den angår også forsøk omfattende: dyrkning av perifert helblod med en testforbindelse; og bestemmelse av effekten av forbindelsen på PGE2-fremkalt helblodcelle-aktivering.
NO20044462A 2002-04-12 2004-10-20 Anvendelse av EP4-reseptorligander i behandling av IL-6 involverte sykdommer NO20044462L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37236402P 2002-04-12 2002-04-12
PCT/IB2003/001310 WO2003086371A2 (en) 2002-04-12 2003-04-03 Use of ep4 receptor ligands in the treatment of il-6 involved diseases

Publications (1)

Publication Number Publication Date
NO20044462L true NO20044462L (no) 2005-01-11

Family

ID=29250846

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20044462A NO20044462L (no) 2002-04-12 2004-10-20 Anvendelse av EP4-reseptorligander i behandling av IL-6 involverte sykdommer

Country Status (19)

Country Link
US (2) US7148234B2 (no)
EP (1) EP1499305A2 (no)
JP (1) JP2005533756A (no)
KR (1) KR100592007B1 (no)
CN (2) CN100579518C (no)
AU (1) AU2003214525B2 (no)
BR (1) BR0309200A (no)
CA (1) CA2481535C (no)
HK (1) HK1076737A1 (no)
IL (1) IL164263A0 (no)
MX (1) MXPA04009243A (no)
MY (1) MY140867A (no)
NO (1) NO20044462L (no)
NZ (1) NZ535748A (no)
PL (1) PL373246A1 (no)
RU (1) RU2285527C2 (no)
TW (1) TW200409636A (no)
WO (1) WO2003086371A2 (no)
ZA (1) ZA200407795B (no)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8017121B2 (en) * 1994-06-30 2011-09-13 Chugai Seiyaku Kabushika Kaisha Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
CZ298325B6 (cs) * 1994-10-21 2007-08-29 Kishimoto@Tadamitsu Farmaceutický prípravek pro prevenci nebo lécení plasmocytosy
US20020187150A1 (en) * 1997-08-15 2002-12-12 Chugai Seiyaku Kabushiki Kaisha Preventive and/or therapeutic agent for systemic lupus erythematosus comprising anti-IL-6 receptor antibody as an active ingredient
CZ297083B6 (cs) * 1998-03-17 2006-09-13 Chugai Seiyaku Kabushiki Kaisha Cinidlo pro prevenci a lécbu zánetlivého onemocnení streva obsahující aktivní slozku antagonistu IL-6
WO2002036165A1 (fr) * 2000-10-27 2002-05-10 Chugai Seiyaku Kabushiki Kaisha Agent à base d'antagoniste d'il-6, faisant baisser le niveau des mmp-3 dans le sang
UA80091C2 (en) * 2001-04-02 2007-08-27 Chugai Pharmaceutical Co Ltd Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
CN101812021B (zh) * 2003-03-13 2012-12-26 出光兴产株式会社 含氮杂环衍生物及使用该衍生物的有机电致发光元件
US7271271B2 (en) * 2004-06-28 2007-09-18 Amgen Sf, Llc Imidazolo-related compounds, compositions and methods for their use
WO2006095268A1 (en) * 2005-03-11 2006-09-14 Pfizer Japan Inc. Crystal forms of an imidazole derivative
UY30121A1 (es) 2006-02-03 2007-08-31 Glaxo Group Ltd Nuevos compuestos
CL2007002994A1 (es) * 2006-10-19 2008-02-08 Wyeth Corp Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros.
NZ577109A (en) 2006-12-15 2011-12-22 Glaxo Group Ltd Benzamide derivatives as ep4 receptor agonists
US7977371B2 (en) 2007-02-26 2011-07-12 Santen Pharmaceutical Co., Ltd. Pyrrole derivative having ureido group and aminocarbonyl group as substituents
GB0721611D0 (en) 2007-11-02 2007-12-12 Glaxo Group Ltd Novel compounds
US20100305098A1 (en) * 2007-11-15 2010-12-02 Qian Chen Methods of use
CA2724077C (en) * 2008-05-14 2016-04-26 Astellas Pharma Inc. Amide compound
JP5492496B2 (ja) 2008-08-25 2014-05-14 参天製薬株式会社 ウレイド基、アミノカルボニル基及び置換基を有してもよい二環式基を置換基として有する新規ピロール誘導体
MX2012000322A (es) 2009-07-17 2012-02-08 Novozymes As Metodo de analisis del decaimiento de la celulosa en la hidrolisis del material celulosico.
JP2013508282A (ja) 2009-10-14 2013-03-07 ジェンムス ファーマ インコーポレイティド ウイルス感染のための併用療法処置
KR101552760B1 (ko) * 2009-12-18 2015-09-11 미쓰비시 타나베 파마 코퍼레이션 신규 항혈소판약
EP2529022A1 (en) 2010-01-29 2012-12-05 Novozymes A/S Biogas production process with enzymatic pre-treatment
CA2789665C (en) 2010-02-22 2020-06-16 Raqualia Pharma Inc. Use of ep4 receptor antagonists in the treatment of il-23 mediated diseases
WO2011123505A1 (en) 2010-03-30 2011-10-06 Novozymes North America, Inc. Processes of producing a fermentation product
EP2601301A1 (en) 2010-08-02 2013-06-12 Novozymes North America, Inc. Process of producing a fermentation product
EP2621885B1 (en) * 2010-09-29 2014-10-29 The Procter and Gamble Company Methods of synthesizing 2-methoxymethyl-1,4-benzenediamine
BR112013012357A2 (pt) 2010-11-19 2016-10-11 Novozymes North America Inc processos de produzir um produto de fermentação, de produzir um açúcar, de produzir uma dextrina e de produzir sacarose, e, composição
JP5986566B2 (ja) 2011-07-07 2016-09-06 イハラケミカル工業株式会社 ニトロベンゼン化合物の製造方法
PL2792667T3 (pl) 2011-12-14 2018-05-30 Kumiai Chemical Industry Co., Ltd. Związek difenyloaminowy i sposób jego wytwarzania
UA115576C2 (uk) 2012-12-06 2017-11-27 Байєр Фарма Акцієнгезелльшафт Похідні бензимідазолу як антагоністи ер4
WO2014208296A1 (ja) 2013-06-25 2014-12-31 イハラケミカル工業株式会社 ニトロベンゼン化合物を製造する方法
CA2920856A1 (en) 2013-08-09 2015-02-12 Ardelyx, Inc. Ph modulating compounds for inhibiting gastrointestinal phosphate uptake
TW201607943A (zh) 2013-12-19 2016-03-01 拜耳製藥公司 作為ｅｐ４配體之新穎苯并咪唑衍生物
MX2016011025A (es) 2014-03-06 2016-11-29 Aratana Therapeutics Inc Composiciones de grapiprant y metodos para usar las mismas.
WO2015143144A1 (en) 2014-03-19 2015-09-24 Novozymes A/S Method for enhancing activity of an x143 polypeptide
US9343949B2 (en) * 2014-09-22 2016-05-17 Texas Instruments Incorporated Control circuit to detect a noise signal during a state change of a switch
EP3072943B1 (en) 2015-03-26 2018-05-02 Idemitsu Kosan Co., Ltd. Dibenzofuran/carbazole-substituted benzonitriles
JP6789526B2 (ja) 2016-05-09 2020-11-25 クミアイ化学工業株式会社 ニトロベンゼン化合物を製造する方法
WO2017207340A1 (de) 2016-05-31 2017-12-07 Bayer Pharma Aktiengesellschaft Neue substituierte benzimidazole, verfahren zu ihrer herstellung, pharmazeutische präparate die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln
MX2021009378A (es) * 2016-06-30 2022-06-29 Daewoong Pharmaceutical Co Ltd Derivados de pirazolopirimidina como inhibidor de cinasa.
WO2018162562A1 (en) 2017-03-10 2018-09-13 Bayer Pharma Aktiengesellschaft Use of an ep4 antagonist for the treatment of inflammatory pain
WO2019038156A1 (en) 2017-08-22 2019-02-28 Bayer Pharma Aktiengesellschaft USE OF AN EP4 ANTAGONIST FOR THE TREATMENT OF ARTHRITIS
US10239885B1 (en) 2018-06-18 2019-03-26 Avista Pharma Solutions, Inc. Compound 1-[2-[4-(2-ethyl-6,8-dimethylimidazo[1,2-α]pyrazin-3-yl)phenyl]ethyl]-3-(p-tolylsulfonyl)urea as a prostaglandin EP4 receptor antagonist
US20210315909A1 (en) * 2018-07-11 2021-10-14 Arrys Therapeutics, Inc. Polymorphic compounds and uses thereof
EP4364798A2 (en) 2018-10-05 2024-05-08 Annapurna Bio Inc. Compounds and compositions for treating conditions associated with apj receptor activity
WO2020160075A1 (en) 2019-01-30 2020-08-06 Avista Pharma Solutions, Inc. Chemical compounds
WO2020160074A1 (en) 2019-01-30 2020-08-06 Avista Pharma Solutions, Inc. Synthetic process and novel intermediates
JP2022533251A (ja) 2019-05-21 2022-07-21 アルデリックス， インコーポレイテッド 患者において血清リン酸塩を低下させるための組み合わせ

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4536507A (en) * 1977-07-26 1985-08-20 Merck & Co., Inc. Prostaglandin antagonists
TW401408B (en) * 1995-07-21 2000-08-11 Fujisawa Pharmaceutical Co Heterocyclic compounds having prostaglandin I2 agonism
AUPP608898A0 (en) * 1998-09-23 1998-10-15 Fujisawa Pharmaceutical Co., Ltd. New use of prostaglandin E2 antagonists
US6437146B1 (en) * 1998-09-25 2002-08-20 Fujisawa Pharmaceutical Co., Ltd. Oxazole compounds as prostaglandin e2 agonists or antagonists
HN2001000224A (es) * 2000-10-19 2002-06-13 Pfizer Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos.
GB0031295D0 (en) * 2000-12-21 2001-01-31 Glaxo Group Ltd Naphthalene derivatives

Also Published As

Publication number Publication date
HK1076737A1 (en) 2006-01-27
CN101023946A (zh) 2007-08-29
PL373246A1 (en) 2005-08-22
US7928119B2 (en) 2011-04-19
AU2003214525B2 (en) 2008-09-25
RU2285527C2 (ru) 2006-10-20
CA2481535A1 (en) 2003-10-23
ZA200407795B (en) 2007-01-31
KR20040105864A (ko) 2004-12-16
US20070066618A1 (en) 2007-03-22
RU2004130320A (ru) 2005-06-10
CA2481535C (en) 2010-08-17
US20030236260A1 (en) 2003-12-25
NZ535748A (en) 2007-06-29
MXPA04009243A (es) 2005-06-08
MY140867A (en) 2010-01-29
JP2005533756A (ja) 2005-11-10
AU2003214525A1 (en) 2003-10-27
US7148234B2 (en) 2006-12-12
TW200409636A (en) 2004-06-16
WO2003086371A2 (en) 2003-10-23
WO2003086371A3 (en) 2004-06-03
BR0309200A (pt) 2005-02-22
KR100592007B1 (ko) 2006-06-21
CN1658847A (zh) 2005-08-24
EP1499305A2 (en) 2005-01-26
CN100579518C (zh) 2010-01-13
IL164263A0 (en) 2005-12-18

Similar Documents

Publication Publication Date Title
NO20044462L (no) Anvendelse av EP4-reseptorligander i behandling av IL-6 involverte sykdommer
FR22C1052I2 (fr) Anticorps anti-cd19 humanises et leur utilisation dans le traitement des tumeurs, de la transplantation et des maladies auto-immunes
HK1070575A1 (en) Use of botulinum toxin for treating cardiovasculardiseases
LTPA2017009I1 (lt) Brutono tirozinkinazės inhibitoriai
IL169896A0 (en) Methods and compositions for administering therapeutic and diagnostic agents
NO20074999L (no) Metode og preparat for behandling av perifere vaskulaere sykdommer
EA200700118A1 (ru) Амидосоединения и их применение в качестве лекарственных средств
TW200510349A (en) Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor
EA200800879A1 (ru) Агонисты ppar гамма для улучшения когнитивной функции у apoe4 отрицательных пациентов
EA200700407A1 (ru) Производные хиназолина и их использования при лечении тромбоцитемии
EA200601212A1 (ru) Ингибиторы фосфодиэстеразы, получение и их терапевтическое применение
RU2008116567A (ru) Биомаркеры
HK1107148A1 (en) Use of anti-robo1 antibody in manufacturing a medicament for treating cancer and related diagnosis kit
MA28981B1 (fr) Anticorps monoclonaux humains diriges contre l'il-4 humaine
ATE516366T1 (de) Regulierte aptamer-therapeutika
DE60319083D1 (de) Pharmazeutische verbindung und methoden zur behandlung von menschlichen karzinomen mittels arginin entzug
EA200401319A1 (ru) Новые гетероциклические соединения, способы их получения и фармацевтические композиции, содержащие эти соединения, и их использование в медицине
RU2007103332A (ru) Способы лечения опосредуемых ccr2 заболеваний или нарушений
WO2020176654A8 (en) Use of caseinolytic protease p function as a biomarker of drug response to imipridone-like agents
ATE383870T1 (de) Behandlung von neurodegenerative krankheiten mit gpr49
DK1611252T3 (da) In vitro-fremgangsmåde til påvisning af overgangscelle-karcinom i blæren
TW200503666A (en) Treatment of type 1 diabetes with pde5 inhibitors
DK1596879T3 (da) Anvendelse af kahalalidforbindelser til fremstilling af et medikament til behandling af psoriasis
ATE369147T1 (de) Verwendung von stimulierten mononuklearen zellen des peripheren blutes zur behandlung von krebserkrankungen
EA201300410A1 (ru) Стратификация страдающих раком пациентов по чувствительности к терапии с использованием ингибиторов ptk2

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application